The Market Reports

Synopsis
The global market for Nicotinamide Mononucleotide (NMN) was estimated to be worth US$ 418 million in 2024 and is forecast to a readjusted size of US$ 992 million by 2031 with a CAGR of 13.4% during the forecast period 2025-2031.
Nicotinamide mononucleotide (NMN) is an intermediate of NAD+ biosynthesis produced from nicotinamide through nicotinamide phosphoribosyltransferase (NAMPT) and also referred to as NMN or nicotinamide ribotide. In recent studies of NMN applications to prevention and diagnosis of age-dependent diseases such as diabetes, neurodegenerative disorder, cardiac disease etc., it has become one of hottest biomarkers on discussion for anti-aging, lately.
NMN is a precursor of nicotinamide adenine dinucleotide (NAD+), which plays a vital role in cell metabolism and energy production. As we age, the level of NAD+ in the human body gradually decreases, resulting in weakened cell metabolism, which in turn triggers a series of aging-related diseases. Therefore, increasing the level of NAD+ in the body by supplementing NMN has become a new way to fight aging and maintain good health.
With the general improvement of global health awareness and continuous breakthroughs in scientific research and technology, the growth momentum of the NMN market will continue to increase. In the future, the NMN market will achieve a deeper cross-border integration with other health industries such as biotechnology, precision medicine, and nutritional supplements, giving rise to a series of innovative products and service models to meet consumers' more personalized and precise health needs.
At present, nicotinamide mononucleotide (NMN) is still in the development stage. There are not many manufacturers in the global market, and consumers have weak awareness of its use, especially in developing countries. The demand is lower than that in developed countries around the world, but the demand in developing countries is growing rapidly. Leading giants have proposed expansion plans and increased production bases.
Nicotinamide mononucleotide (NMN) core manufacturers include GeneHarbor, Mirailab Bioscience, Maac10 Formulas, Herbalmax and Genex Formula. China is the largest production area, accounting for about 84% of the global market share, followed by North America and Japan. The downstream applications of nicotinamide mononucleotide include health products, cosmetics, etc. Globally, health products are the largest application market, and raw materials for health products account for 99% of the total sales of nicotinamide mononucleotide in 2023.
This report aims to provide a comprehensive presentation of the global market for Nicotinamide Mononucleotide (NMN), focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Nicotinamide Mononucleotide (NMN) by region & country, by Type, and by Application.
The Nicotinamide Mononucleotide (NMN) market size, estimations, and forecasts are provided in terms of sales volume (Tons) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nicotinamide Mononucleotide (NMN).
Market Segmentation
By Company
GeneHarbor
Herbalmax
Genex Formulas
Mirailab Bioscience
Maac10 Formulas
EffePharm
Bontac
CELFULL
Kingdomway
ABA Chemical
Segment by Type
Content ≥98%
Content ＜98%
Segment by Application
Health Care Products
Cosmetics
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Nicotinamide Mononucleotide (NMN) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Nicotinamide Mononucleotide (NMN) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Nicotinamide Mononucleotide (NMN) in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Index